Filing Flows › Altria Group (MO) › Q3 2026 › vs Q3 2025
Altria Group (MO) Q3 2026 vs Q3 2025 (year over year)
Altria Group's revenue rose $60.0M (+1%) from $6.1B in Q3 2025 to $6.1B in Q3 2026. The biggest changes: Smokeable Products Segment +$45.0M (+0.8%); All Other +$16.0M (—); Oral Tobacco Segment −$1.0M (-0.1%). Gross margin 64.3% against 62.8% (+1.5 pts).
Altria Group, Q3 2026: revenue $6.1B (+1% year over year), operating margin 54.0%, net earnings $2.5B, operating cash flow $3.1B. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 64.3% | 62.8% | +1.5 pts |
| Operating margin | 54.0% | 53.2% | +0.8 pts |
| Net margin | 41.0% | 39.1% | +1.9 pts |
| Free cash flow margin | 48.9% | 50.1% | -1.2 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Smokeable Products Segment | $5.4B | $5.4B | $45.0M | +0.8% |
| Oral Tobacco Segment | $688M | $689M | −$1.0M | -0.1% |
| All Other | $12.0M | −$4.0M | $16.0M | — |
| Revenue | $6.1B | $6.1B | $60.0M | +1% |
| Gross profit | $3.9B | $3.8B | $129M | +3% |
| Cost of revenue | $2.2B | $2.3B | −$69.0M | -3% |
| Operating profit | $3.3B | $3.2B | $83.0M | +3% |
| Operating expenses | $628M | $582M | $46.0M | +8% |
| Pre-tax earnings | $3.3B | $3.1B | $215M | +7% |
| Other expense, net | $23.0M | $155M | −$132M | -85% |
| Net earnings | $2.5B | $2.4B | $139M | +6% |
| Income tax | $776M | $700M | $76.0M | +11% |
| Depreciation & amortization | $60.0M | $70.0M | −$10.0M | -14% |
| Working capital & other | $534M | $649M | −$115M | -18% |
| Operating cash flow | $3.1B | $3.1B | $14.0M | +0.5% |
| Free cash flow (OCF − capex) | $3.0B | $3.0B | −$41.0M | -1% |
| Capital expenditures | $109M | $54.0M | $55.0M | +102% |
Questions
How much did Altria Group's revenue grow year over year in Q3 2026?
Altria Group's revenue rose $60.0M (+1%) from $6.1B in Q3 2025 to $6.1B in Q3 2026.
What drove Altria Group's revenue change in Q3 2026?
Smokeable Products Segment +$45.0M (+0.8%); All Other +$16.0M (—); Oral Tobacco Segment −$1.0M (-0.1%).